Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein.

Abstract:

:Recombinant plasmid DNA constructs expressing truncated or full-length dengue-1 envelope (E) with or without the pre-membrane (prM) were tested for immunogenicity in mice, as candidate dengue DNA vaccines. Two plasmids, one expressing the N-terminal 80% E and the other expressing prM and full length E were immunogenic in intradermally inoculated mice. The vaccinated mice produced dengue-1 specific antibodies that were both neutralizing and long lasting. Data suggested that the plasmid expressing prM and full length E produced virus like particles in transfected cells, and is probably a better immunogen compared to that expressing 80% E.

journal_name

Vaccine

journal_title

Vaccine

authors

Raviprakash K,Kochel TJ,Ewing D,Simmons M,Phillips I,Hayes CG,Porter KR

doi

10.1016/s0264-410x(99)00570-8

subject

Has Abstract

pub_date

2000-05-08 00:00:00

pages

2426-34

issue

22

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(99)00570-8

journal_volume

18

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Measles and rubella immunity in the population of Bhutan, 2017.

    abstract:BACKGROUND:In 2017, measles elimination was verified in Bhutan, and the country appears to have sufficiently high vaccination coverage to achieve rubella elimination. However, a measles and rubella serosurvey was conducted to find if any hidden immunity gaps existed that could threaten Bhutan's elimination status. MET...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.08.085

    authors: Wangchuk S,Nogareda F,Tshering N,Khandu L,Pelden S,Wannemuehler K,Wangdi S,Wangchuk U,Mulders M,Tamang T,Patel MK

    更新日期:2019-10-08 00:00:00

  • Reducing pain at the time of vaccination: WHO position paper, September 2015-Recommendations.

    abstract::This article presents the World Health Organization's (WHO) recommendations for pain mitigation at the time of vaccination from the WHO position paper on reducing pain at the time of vaccination: WHO position paper-September 2015, recently published in the Weekly Epidemiological Record [1]. This position paper summari...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.11.005

    authors: WHO.

    更新日期:2016-07-12 00:00:00

  • Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.

    abstract::A post hoc analysis was performed using combined data from two Phase I tolerability/immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 virus-like particle (VLP) vaccines. The goal was to determine if the HPV16 L1 VLP vaccine protected against HPV16 infection. Vaccine or placebo was g...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2003.11.059

    authors: Brown DR,Fife KH,Wheeler CM,Koutsky LA,Lupinacci LM,Railkar R,Suhr G,Barr E,Dicello A,Li W,Smith JF,Tadesse A,Jansen KU

    更新日期:2004-07-29 00:00:00

  • A combination vaccine confers full protection against co-infections with influenza, herpes simplex and respiratory syncytial viruses.

    abstract::Combined/composite vaccines should be useful in reducing the number of vaccinations and provide more flexibility in confronting biological warfare scenarios. We tested the effectiveness of a composite genetic vaccine designed from previously known protective antigens directed against influenza A virus (INF-A), herpes ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00352-8

    authors: Talaat AM,Lyons R,Johnston SA

    更新日期:2001-11-12 00:00:00

  • Immunisation practices in centres caring for children with perinatally acquired HIV: A call for harmonisation.

    abstract:BACKGROUND:Current national immunisation schedules differ between countries in terms of vaccine formulation, timing of vaccinations and immunisation programme funding and co-ordination. As a result, some HIV infected paediatric population may be left susceptible to vaccine preventable infections. Vaccines used in healt...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.vaccine.2016.09.035

    authors: Bamford A,Manno EC,Mellado MJ,Spoulou V,Marques L,Scherpbier HJ,Niehues T,Oldakowska A,Rossi P,Palma P,PENTA-vac Group.

    更新日期:2016-11-04 00:00:00

  • Production of yellow fever virus in microcarrier-based Vero cell cultures.

    abstract::In this work, the propagation of the 17DD yellow fever virus in Vero cells grown on Cytodex-1 microcarriers was evaluated. After verifying that upon infection the virus adsorption step could be performed under continuous agitation, experiments were carried out in spinners and sparged lab-scale stirred-tank bioreactor ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.06.023

    authors: Souza MC,Freire MS,Schulze EA,Gaspar LP,Castilho LR

    更新日期:2009-10-30 00:00:00

  • Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine.

    abstract::Here, monophosphoryl lipid A (MPLA) and aluminum salt (Alum) were introduced into a hyaluronic acid (HA)-based combination vaccine adjuvant for hepatitis B vaccine (HBV). Although Alum is a well-known hepatitis B vaccine adjuvant that induces an enhanced humoral immune response, it cannot induce the cellular immune re...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.08.006

    authors: Moon SH,Shin EC,Noh YW,Lim YT

    更新日期:2015-09-11 00:00:00

  • Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

    abstract::Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenici...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2006.04.068

    authors: Villa LL,Ault KA,Giuliano AR,Costa RL,Petta CA,Andrade RP,Brown DR,Ferenczy A,Harper DM,Koutsky LA,Kurman RJ,Lehtinen M,Malm C,Olsson SE,Ronnett BM,Skjeldestad FE,Steinwall M,Stoler MH,Wheeler CM,Taddeo FJ,Yu J,

    更新日期:2006-07-07 00:00:00

  • Monoclonal antibodies for prophylactic and therapeutic use against viral infections.

    abstract::Neutralizing antibodies play an essential part in antiviral immunity and are instrumental in preventing or modulating viral diseases. Polyclonal antibody preparations are increasingly being replaced by highly potent monoclonal antibodies (mAbs). Cocktails of mAbs and bispecific constructs can be used to simultaneously...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2013.01.025

    authors: Both L,Banyard AC,van Dolleweerd C,Wright E,Ma JK,Fooks AR

    更新日期:2013-03-15 00:00:00

  • DNA adjuvant Amiloride conjunct long immunization interval promote higher antibody responses to HIV-1 gp41 and gp140 immunogens.

    abstract::Recent studies have revealed that the interface of gp120 and gp41 and some parts of gp41 are also critical epitopes for elicitation of broadly neutralizing antibodies. Therefore, potential trimeric gp41 or gp140 immunogen candidates are needed. Previously, we developed a trimer motif MTQ and demonstrated that it could...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.09.077

    authors: Yao L,Wang JY,Bao LN,Fan MX,Bai Y,Chen WJ,Yuan C,Yuan L,Wang J,Li Y,Zhuang M,Ling H

    更新日期:2020-11-03 00:00:00

  • Successful DNA immunisation of rats against fasciolosis.

    abstract::The liver fluke Fasciola hepatica contributes to great economic and health losses in the cattle industry in many countries, including Poland. Unfortunately, no vaccine against fasciolosis is commercially available. We have designed a DNA vaccine and tested it in rats. Groups of male or female rats received one intramu...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(00)00095-5

    authors: Kofta W,Mieszczanek J,Płucienniczak G,Wedrychowicz H

    更新日期:2000-07-01 00:00:00

  • Vaccination for control of Salmonella in poultry.

    abstract::Salmonella spp. are facultative intracellular pathogens causing localised or systemic infections, in addition to a chronic asymptomatic carrier state. They are of worldwide economic and public health significance. In poultry, which represent important sources of cheap protein throughout the world, fowl typhoid and pul...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/s0264-410x(99)00060-2

    authors: Zhang-Barber L,Turner AK,Barrow PA

    更新日期:1999-06-04 00:00:00

  • Crossreactive neutralizing antibodies induced by immunization with caprine arthritis-encephalitis virus surface glycoprotein.

    abstract::Four Saanen goats were immunized with affinity purified gp135 surface glycoprotein (SU) of caprine arthritis-encephalitis virus isolate 79-63 (CAEV-63) and evaluated for homologous and crossreactive serum neutralizing antibodies. CAEV-63 neutralizing antibodies were detected in all goats after seven immunizations with...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00181-4

    authors: Kemp RK,Knowles DP,Perry LL,McGuire TC,Besser TE,Cheevers WP

    更新日期:2000-01-18 00:00:00

  • Beta-propiolactone treatment impairs the biological activity of residual DNA from BHK-21 cells infected with rabies virus.

    abstract::The effects of beta-propiolactone (BPL), an alkylating and virus inactivating agent, on the structural and in vitro biological properties of different DNA preparations from BHK-21 cells were investigated. Both uninfected and rabies virus-infected cells were used. Purified cellular DNA (celDNA) was used as the referenc...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(93)90343-v

    authors: Morgeaux S,Tordo N,Gontier C,Perrin P

    更新日期:1993-01-01 00:00:00

  • Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys.

    abstract::The immunogenicity of two meningococcal outer membrane vesicle (OMV) vaccines, namely the Norwegian wild-type OMV vaccine and the Dutch hexavalent PorA OMV vaccine, were examined in infant cynomolgus monkeys. For the first time, a wild-type- and a recombinant OMV vaccine were compared. Furthermore, the induction of me...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00402-8

    authors: Rouppe van der Voort E,Schuller M,Holst J,de Vries P,van der Ley P,van den Dobbelsteen G,Poolman J

    更新日期:2000-01-31 00:00:00

  • A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.

    abstract::We tested a candidate live, oral, rotavirus vaccine (Rotavin-M1™) derived from an attenuated G1P [8] strain (KH0118-2003) isolated from a child in Vietnam. The vaccine was tested first for safety in 29 healthy adults. When deemed safe, it was further tested for safety and immunogenicity in 160 infants (4 groups) aged ...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2011.07.118

    authors: Dang DA,Nguyen VT,Vu DT,Nguyen TH,Nguyen DM,Yuhuan W,Baoming J,Nguyen DH,Le TL,Rotavin-M1 Vaccine Trial Group.

    更新日期:2012-04-27 00:00:00

  • Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques.

    abstract::Optimized DNA vectors were constructed comprising the proteome of SIV including the structural, enzymatic, regulatory, and accessory proteins. In addition to native antigens as produced by the virus, fusion proteins and modified antigens with altered secretion, cellular localization and stability characteristics were ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.12.056

    authors: Kulkarni V,Jalah R,Ganneru B,Bergamaschi C,Alicea C,von Gegerfelt A,Patel V,Zhang GM,Chowdhury B,Broderick KE,Sardesai NY,Valentin A,Rosati M,Felber BK,Pavlakis GN

    更新日期:2011-09-09 00:00:00

  • The path towards effective antivirals against rabies.

    abstract::Rabies virus remains an important burden of disease claiming an estimated 60,000 lives each year, mainly children, and having a huge economical and societal cost. Post-exposure prophylaxis (PEP) is highly effective, however in patients that present with neurological symptoms the case-fatality ratio is extremely high (...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2017.12.051

    authors: Jochmans D,Neyts J

    更新日期:2019-08-02 00:00:00

  • Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli.

    abstract::Using a fixed dose of antigen, the immune response to detoxified mutants of LT-WT following intranasal (i.n.), subcutaneous (s.c.) and oral (i.g.) immunisation has been studied. When given i.n., both LT-WT and mutant toxin, K63, generated significant levels of toxin-specific IgG in the serum, and the levels of IgA in ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(98)80100-x

    authors: Douce G,Giuliani MM,Giannelli V,Pizza MG,Rappuoli R,Dougan G

    更新日期:1998-07-01 00:00:00

  • Measles vaccine adverse events reported in the mass vaccination campaign of Sichuan province, China from 2007 to 2008.

    abstract::The aim of this study was to characterize the adverse events of attenuated measles vaccine in mainland China. We carried out prospective follow-up of adverse events after mass measles immunization practices, categorizing them into two groups: allergic reactions and serious adverse events. The incidence of anaphylaxis ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.10.106

    authors: Shu M,Liu Q,Wang J,Ao R,Yang C,Fang G,Wan C,Guo W

    更新日期:2011-04-18 00:00:00

  • Intranasal inoculate of influenza virus vaccine against lethal virus challenge.

    abstract::Vaccine adjuvants are essential for enhancing immune responses during vaccination. However, only a limited number of safe and effective adjuvants, especially mucosal adjuvants, are available for use in vaccines. The development of a practically applicable mucosal adjuvant is therefore urgently needed. Here, we showed ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.05.075

    authors: Fan X,Su Q,Qiu F,Yi Y,Shen L,Jia Z,Liang P,Zou Y,Bi S

    更新日期:2018-07-05 00:00:00

  • Proximity to safety-net clinics and HPV vaccine uptake among low-income, ethnic minority girls.

    abstract:PURPOSE:Human Papillomavirus (HPV) vaccine uptake remains low. Although publicly funded programs provide free or low cost vaccines to low-income children, barriers aside from cost may prevent disadvantaged girls from getting vaccinated. Prior studies have shown distance to health care as a potential barrier to utilizin...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.02.046

    authors: Tsui J,Singhal R,Rodriguez HP,Gee GC,Glenn BA,Bastani R

    更新日期:2013-04-12 00:00:00

  • Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2.

    abstract::Vector-directed lymphokine expression represents a novel approach to the attenuation of live recombinant viruses which might be used as vaccines. Expression of interleukin-2 (IL-2) by recombinant vaccinia virus has been shown to significantly attenuate virus virulence in rodent species without diminishing immunogenici...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(90)90171-h

    authors: Flexner C,Moss B,London WT,Murphy BR

    更新日期:1990-02-01 00:00:00

  • Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves.

    abstract::Two modified live attenuated vaccines against the disease Rift Valley fever (RVF) have been tested for safety and efficacy in young calves. The RVF Smithburn vaccine produced in South Africa and used successfully to prevent and control the disease in endemic sub-Saharan countries was compared to the candidate vaccine ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.05.055

    authors: von Teichman B,Engelbrecht A,Zulu G,Dungu B,Pardini A,Bouloy M

    更新日期:2011-08-05 00:00:00

  • Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation.

    abstract::This study investigated the immune response and safety in 430 adults, when boosted more than 3 years after primary or booster TBE immunisation as measured by neutralization test (NT) and ELISA. Tested by NT, the post-booster day 21 geometric mean titer (GMT) was 331 and 142 for the 18-49 and > or =50 years old, respec...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.vaccine.2004.07.002

    authors: Rendi-Wagner P,Kundi M,Zent O,Banzhoff A,Jaehnig P,Stemberger R,Dvorak G,Grumbeck E,Laaber B,Kollaritsch H

    更新日期:2004-12-09 00:00:00

  • An alternative signal 3: CD8⁺ T cell memory independent of IL-12 and type I IFN is dependent on CD27/OX40 signaling.

    abstract::Type I IFN and IL-12 are well documented to serve as so called "signal 3" cytokines, capable of facilitating CD8(+) T cell proliferation, effector function and memory formation. While their ability to serve in this capacity is well established, to date, no non-cytokine signal 3 mediators have been clearly identified. ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.12.017

    authors: Sanchez PJ,Kedl RM

    更新日期:2012-02-01 00:00:00

  • Enterobactin-specific antibodies inhibit in vitro growth of different gram-negative bacterial pathogens.

    abstract::Enterobactin (Ent)-mediated high affinity iron acquisition is critically important for Gram-negative bacterial pathogens to survive and infect the host. Recently, we reported an efficient method to prepare novel Ent conjugate vaccines for inducing high level of Ent-specific antibodies, which displayed similar bacterio...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.10.040

    authors: Wang H,Zeng X,Lin J

    更新日期:2020-11-17 00:00:00

  • Implementing universal vaccination programmes: USA.

    abstract::In the USA, the policy is that all infants receive vaccine against hepatitis B virus (HBV). It is considered that HBV vaccine can be readily integrated into the routine childhood immunization schedule without additional visits. Booster doses of vaccine are not currently recommended because protection lasts for at leas...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(95)80060-q

    authors: Kane M

    更新日期:1995-01-01 00:00:00

  • Implementation of good clinical practice guidelines in vaccine trials in developing countries.

    abstract::The practicalities when applying the ICH GCPs (International Conference on Harmonization 1996 Good Clinical Practices [EU, MHLW, FDA. International Conference on Harmonization Guideline for Good Clinical Practice; 1997] in less developed countries (ldcs) are seldom discussed and we found no guidelines as how to "adapt...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.09.079

    authors: Acosta CJ,Galindo CM,Ochiai RL,Danovaro-Holliday MC,Laure-Page A,Thiem VD,Jin Y,Khan MI,Sahito SM,Hamza HB,Park JK,Lee H,Bock H,Elyazeed RA,Albert MJ,Ascaso C,Robles TQ,Ali M,Ngai P,Puri MK,Koo YM,Agtini MD,So

    更新日期:2007-04-12 00:00:00

  • Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.

    abstract:BACKGROUND:IXIARO® is a Vero cell-derived, inactivated Japanese encephalitis (JE) vaccine licensed mainly in western countries for children and adults traveling to JE endemic areas. Limited immunogenicity and safety data in elderly travelers have been available. OBJECTIVES:To evaluate safety and immunogenicity of IXIA...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.vaccine.2016.07.029

    authors: Cramer JP,Dubischar K,Eder S,Burchard GD,Jelinek T,Jilma B,Kollaritsch H,Reisinger E,Westritschnig K

    更新日期:2016-08-31 00:00:00